跳转至内容
Merck
CN

PZ0280

CP-456773 钠盐

≥98% (HPLC), powder, IL-1β secretion inhibitor

别名:

CRID3, MCC950, N-[[(1,2,3,5,6,7-六氢-s-吲达辛-4-基)氨基]羰基] -4-(1-羟基-1-甲基乙基)-2-呋喃磺酰胺 钠盐, 细胞因子释放抑制药物 3

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H23N2NaO5S
化学文摘社编号:
分子量:
426.46
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

CP-456773 钠盐, ≥98% (HPLC)

SMILES string

CC(O)(C)C1=COC(S([N-]C(NC2=C(CCC3)C3=CC4=C2CCC4)=O)(=O)=O)=C1.[Na+]

InChI

1S/C20H24N2O5S.Na/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18;/h9-11,24H,3-8H2,1-2H3,(H2,21,22,23);/q;+1/p-1

InChI key

LFQQNXFKPNZRFT-UHFFFAOYSA-M

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 20 mg/mL, clear

storage temp.

room temp

Quality Level

Application

CP-456773钠盐已用于:
  • 体内实验中研究生酮饮食的神经保护作用。
  • 研究抑制 NLRP3(nod样受体蛋白3)炎性体活性对小鼠模型肿瘤进展的影响。
  • 研究胆固醇晶体介导的IL-1b(白细胞介素-1b)在胎盘外植体中的反应。

Biochem/physiol Actions

CP-456773钠盐(CRID3)是一种细胞因子释放抑制药物,也是NLRP3 炎性体的抑制剂。CP-456773钠盐抑制白细胞介素1β(IL-1β)分泌和caspase 1 加工。
已知 CP-456773抑制其他促炎细胞因子(如IL-1α和IL-18)的释放。它也被称为MCC950。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation.
Primiano M J, et al.
Journal of Immunology, 197(6), 2421-2433 (2016)
Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.
Chen L, et al.
Cellular and Molecular Life Sciences, 75(11), 2045-2058 (2018)
Haining Wang et al.
Life sciences, 227, 101-113 (2019-04-20)
NLRP3 inflammasome has been reported associated with some inflammatory and autoimmune diseases. We previously researches showed that interleukin-23 (IL-23) and interleukin-17 (IL-17) aggravates the ischaemic injury of the brain tissue. However, it is poorly understood whether the NLPR3 inflammasome was
Xintong Jiang et al.
JACC. Basic to translational science, 4(3), 304-317 (2019-07-18)
CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study) confirmed interleukin (IL)-1β as an appealing therapeutic target for human atherosclerosis and related complications. However, there are serious gaps in our understanding of IL-1 production in atherosclerosis. Herein the authors show that complex plaques
Ketogenic Diet Improves Brain Ischemic Tolerance and Inhibits NLRP3 Inflammasome Activation by Preventing Drp1-Mediated Mitochondrial Fission and Endoplasmic Reticulum Stress.
Guo M, et al.
Frontiers in Molecular Neuroscience, 11, 86-86 (2018)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持